BioStem Technologies Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: $7.9 million, up from $6.1 million in Q1 2026.

Hospital Revenue: $6.7 million, compared to $5.4 million in Q1; Physician office revenue increased to $1.1 million from $772,000.

Gross Profit: $4.8 million, maintaining a gross margin of 61%.

Operating Expenses: $13.2 million, up from $12.6 million in Q1, primarily due to investment in the commercial organization.

Net Loss: $9 million, or $0.52 per share, compared to a net income of $10,000 in Q2 2025.

Adjusted EBITDA Loss: $4.6 million, compared to an adjusted EBITDA income of $2.5 million in Q2 2025.

Cash Position: $7 million as of June 30, 2026, down from $13.7 million at the end of Q1.

2Strategic Updates and Business Highlights

Transitioned to a hospital-focused business model, completing the integration of internal systems and commercial organization.

Successfully uplisted to Nasdaq on August 7, 2026, enhancing visibility and access to capital.

Expanded the sales force to over 40 representatives and 30 independent agents, aiming to increase product adoption in hospitals.

Introduced BioRetain dry products to the hospital sales organization and received eight new design patents for product differentiation.

Continued progress on the product roadmap, anticipating the launch of the first 510(k) cleared product later in 2026.

3Forward Guidance and Outlook

Revenue Guidance: Raised full-year 2026 revenue guidance to $26 million-$29 million, up from $25 million-$29 million.

Expect continued sequential growth in the hospital business driven by increased sales rep productivity and GPO account utilization.

Anticipate gradual recovery in the physician office market but remain cautious about its contribution to overall revenue.

Operating expenses expected to remain flat for the remainder of the year, excluding costs related to the Nasdaq uplisting.

4Bad News, Challenges, or Points of Concern

Net Loss: Significant net loss of $9 million raises concerns about profitability and cash burn.

Cash Position: Decreased cash reserves may limit flexibility for future investments or operational needs.

Gross Margin Pressure: Anticipated modest gross margin pressure in the second half of the year due to existing inventory purchased at a discount.

Contingent Consideration: A $10 million contingent payment due in August raises questions about liquidity and financing options.

5Notable Q&A Insights

Management is exploring financing options to meet the $10 million contingent payment, indicating potential liquidity concerns.

The physician office market is expected to contribute 10%-15% of revenue, with the hospital segment remaining the primary focus.

Current sales are well-distributed between Neox and Clarix product lines, with foot and ankle procedures being the largest revenue drivers.

Management remains optimistic about gross margin improvement post-technology transfer, targeting a potential increase of 15-20 percentage points once manufacturing is in-house. This summary encapsulates the key financial metrics, strategic initiatives, forward-looking guidance, challenges, and insights from the Q&A session, providing a comprehensive overview of BioStem Technologies' performance and outlook for Q2 2026.